Rein Therapeutics Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.27 | $-0.10 | +63.0% | Beat |
| Q12026 FY2026 | $-0.49 | $-0.19 | +61.2% | Beat |
| Q42025 FY2025 | $-0.24 | $-0.36 | -50.0% | Miss |
Back to RNTX overview · RNTX holders · RNTX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.